[1]
Xu, X.; Zhao, J.; Xu, Z.; Peng, B.; Huang, Q.; Arnold, E.; Ding, J. Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity. J. Biol. Chem., 2004, 279(32), 33946-33957.
[2]
Haselbeck, R.J.; McAlister-Henn, L. Function and expression of yeast mitochondrial NAD- and NADP-specific isocitrate dehydrogenases. J. Biol. Chem., 1993, 268(16), 12116-12122.
[3]
Jennings, G.T.; Sechi, S.; Stevenson, P.M.; Tuckey, R.C.; Parmelee, D.; McAlister-Henn, L. Cytosolic NADP(+)-dependent isocitrate dehydrogenase-isolation of rat cDNA and study of tissue-specific and developmental expression of mRNA. J. Biol. Chem., 1994, 269(37), 23128-23134.
[4]
Parsons, D.W.; Jones, S.; Zhang, X.S.; Lin, J.C.H.; Leary, R.J.; Angenendt, P.; Mankoo, P.; Carter, H.; Siu, I.M.; Gallia, G.L.; Olivi, A.; McLendon, R.; Rasheed, B.A.; Keir, S.; Nikolskaya, T.; Nikolsky, Y.; Busam, D.A.; Tekleab, H.; Diaz, L.A., Jr; Hartigan, J.; Smith, D.R.; Strausberg, R.L.; Marie, S.K.N.; Shinjo, S.M.O.; Yan, H.; Riggins, G.J.; Bigner, D.D.; Karchin, R.; Papadopoulos, N.; Parmigiani, G.; Vogelstein, B.; Velculescu, V.E.; Kinzler, K.W. An integrated genomic analysis of human glioblastoma multiforme. Science, 2008, 321(5897), 1807-1812.
[5]
Xu, W.; Yang, H.; Liu, Y.; Yang, Y.; Kim, S.H.; Ito, S.; Yang, C.; Wang, P.; Xiao, M.T.; Liu, L.X.; Jiang, W.Q.; Liu, J.; Zhang, J.Y.; Wang, B.; Frye, S.; Zhang, Y.; Xu, Y.H.; Lei, Q.Y.; Guan, K.L.; Zhao, S.M.; Xiong, Y. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell, 2011, 19(1), 17-30.
[6]
Figueroa, M.E.; Abdel-Wahab, O.; Lu, C.; Ward, P.S.; Patel, J.; Shih, A.; Li, Y.S.; Bhagwat, N.; Vasanthakumar, A.; Fernandez, H.F.; Tallman, M.S.; Sun, Z.X.; Wolniak, K.; Peeters, J.K.; Liu, W.; Choe, S.E.; Fantin, V.R.; Paietta, E.; Löwenberg, B.; Licht, J.D.; Godley, L.A.; Delwel, R.; Valk, P.J.M.; Thompson, C.B.; Levine, R.L.; Melnick, A. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell, 2010, 18(6), 553-567.
[7]
Amary, M.F.; Bacsi, K.; Maggiani, F.; Damato, S.; Halai, D.; Berisha, F.; Pollock, R.; O’Donnell, P.; Grigoriadis, A.; Diss, T.; Eskandarpour, M.; Presneau, N.; Hogendoorn, P.C.; Futreal, A.; Tirabosco, R.; Flanagan, A.M. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J. Pathol., 2011, 224(3), 334-343.
[8]
Gross, S.; Cairns, R.A.; Minden, M.D.; Driggers, E.M.; Bittinger, M.A.; Jang, H.G.; Sasaki, M.; Jin, S.; Schenkein, D.P.; Su, S.M.; Dang, L.; Fantin, V.R.; Mak, T.W. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J. Exp. Med., 2010, 207(2), 339-344.
[9]
Hartmann, C.; Meyer, J.; Balss, J.; Capper, D.; Mueller, W.; Christians, A.; Felsberg, J.; Wolter, M.; Mawrin, C.; Wick, W.; Weller, M.; Herold-Mende, C.; Unterberg, A.; Jeuken, J.W.M.; Wesseling, P.; Reifenberger, G.; von Deimling, A. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol., 2009, 4(118), 469-474.
[10]
Marcucci, G.; Maharry, K.; Wu, Y.Z.; Radmacher, M.D.; Mrózek, K.; Margeson, D.; Holland, K.B.; Whitman, S.P.; Becker, H.; Schwind, S.; Metzeler, K.H.; Powell, B.L.; Carter, T.H.; Kolitz, J.E.; Wetzler, M.; Carroll, A.J.; Baer, M.R.; Caligiuri, M.A.; Larson, R.A.; Bloomfield, C.D. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: A cancer and leukemia group B study. J. Clin. Oncol., 2010, 28(14), 2348-2355.
[11]
Amary, M.F.; Bacsi, K.; Maggiani, F.; Damato, S.; Halai, D.; Berisha, F.; Pollock, R.; O’Donnell, P.; Grigoriadis, A.; Diss, T.; Eskandarpour, M.; Presneau, N.; Hogendoorn, P.C.; Futreal, A.; Tirabosco, R.; Flanagan, A.M. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J. Pathol., 2011, 224(3), 334-343.
[12]
Prensner, J.R.; Chinnaiyan, A.M. Metabolism unhinged: IDH mutations in cancer. Nat. Med., 2011, 17(3), 291-293.
[13]
Dang, L.; Jin, S.; Su, S.M. IDH mutations in glioma and acute myeloid leukemia. Trends Mol. Med., 2010, 16(9), 387-397.
[14]
Dang, L.; White, D.W.; Cross, S.; Bennett, B.D.; Bittinger, M.A.; Driggers, E.M.; Fantin, V.R.; Jang, H.G.; Jin, S.; Keenan, M.C.; Marks, K.M.; Prins, R.M.; Ward, P.S.; Yen, K.E.; Liau, L.M.; Rabinowitz, J.D.; Cantley, L.C.; Thompson, C.B.; Heiden, M.G.V.; Su, S.M. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature, 2009, 465(7300), 739-744.
[15]
Ward, P.S.; Patel, J.; Wise, D.R.; Abdel-Wahab, O.; Bennett, B.D.; Coller, H.A.; Cross, J.R.; Fantin, V.R.; Hedvat, C.V.; Perl, A.E.; Rabinowitz, J.D.; Carroll, M.; Su, S.M.; Sharp, K.A.; Levine, R.L.; Thompson, C.B. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell, 2010, 17(3), 225-234.
[16]
Yan, H.; Parsons, D.W.; Jin, G.L.; McLendon, R.; Rasheed, B.A.; Yuan, W.S.; Kos, I.; Batinic-Haberle, I.; Jones, S.; Riggins, G.J.; Friedman, H.; Friedman, A.; Reardon, D.; Herndon, J.; Kinzler, K.W.; Velculescu, V.E.; Vogelstein, B.; Bigner, D.D. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med., 2009, 360(8), 765-773.
[17]
Chen, J.; Yang, J.; Cao, P. The evolving landscape in the development of isocitrate dehydrogenase mutant inhibitors. Mini Rev. Med. Chem., 2016, 16(16), 1344-1358.
[18]
Wang, F.; Travins, J.; DeLaBarre, B.; Penard-Lacronique, V.; Schalm, S.; Hansen, E.; Straley, K.; Kernytsky, A.; Liu, W.; Gliser, C.; Yang, H.; Gross, S.; Artin, E.; Saada, V.; Mylonas, E.; Quivoron, C.; Popovici-Muller, J.; Saunders, J.O.; Salituro, F.G.; Yan, S.; Murray, S.; Wei, W.; Gao, Y.; Dang, L.; Dorsch, M.; Agresta, S.; Schenkein, D.P.; Biller, S.A.; Su, S.M.; de Botton, S.; Yen, K.E. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science, 2013, 340(6132), 622-626.
[19]
Yen, K.; Travins, J.; Wang, F.; David, M.D.; Artin, E.; Straley, K.; Padyana, A.; Gross, S.; DeLaBarre, B.; Tobin, E.; Chen, Y.; Nagaraja, R.; Choe, S.; Jin, L.; Konteatis, Z.; Cianchetta, G.; Saunders, J.O.; Salituro, F.G.; Quivoron, C.; Opolon, P.; Bawa, O.; Saada, V.; Paci, A.; Broutin, S.; Bernard, O.A.; de Botton, S.; Marteyn, B.S.; Pilichowska, M.; Xu, Y.; Fang, C.; Jiang, F.; Wei, W.; Jin, S.; Silverman, L.; Liu, W.; Yang, H.; Dang, L.; Dorsch, M.; Penard-Lacronique, V.; Biller, S.A.; Su, S.M. AG-221, an first-in-class therapy targeting acute myeloid leukemia harboring oncogenic IDH2 mutations. Cancer Discov., 2017, 7(5), 478-493.
[20]
Agios Pharmaceuticals, Inc. Therapeutically active compounds and
their methods of use. W.O. Patent 2013102431, January 15,2015..
[21]
Wang, F.Y.; Li, Z.L.; Zhang, T.; Yan, G.Y.; Hu, M.X.; Zhao, L.F.; Zhao, Y.L.; Chen, Y.W. Discovery of a novel class of pyridine derivatives that selectively inhibits mutant isocitrate dehydrogenase 2. Chem. Biol. Drug Des., 2018, 91(6), 1087-1093.
[22]
Lu, W.; Liu, X.; Cao, X.; Xue, M.; Liu, K.; Zhao, Z.; Shen, X.; Jiang, H.; Huang, J.; Li, H. SHAFTS: A hybrid approach for 3D molecular similarity calculation. 2. prospective case study in the discovery of diverse p90 ribosomal S6 protein kinase 2 inhibitors to suppress cell migration. J. Med. Chem., 2011, 54(10), 3564-3574.
[23]
Wu, G.S.; Robertson, D.H.; Brooks, C.L.; Vieth, M. Detailed analysis of grid-based molecular docking: A case study of CDOCKER-A CHARMm-based MD docking algorithm. J. Comput. Chem., 2003, 24(13), 1549-1562.
[24]
Baell, J.B.; Holloway, G.A. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J. Med. Chem., 2010, 53(7), 2719-2740.
[25]
Zou, F.X.; Pusch, S.; Eisel, J.; Ma, T.F.; Zhu, Q.H.; Deng, D.W.; Gu, Y.Q.; Xu, Y.G.; von Deimling, A.; Zha, X.M. Identification of a novel selective inhibitor of mutant isocitrate dehydrogenase 1 at allosteric site by docking-based virtual screening. RSC Advances, 2016, 6(99), 96735-96742.
[26]
Pusch, S.; Schweizer, L.; Beck, A.C.; Lehmler, J.M.; Weissert, S.; Balss, J.; Miller, A.K.; von Deimling, A. D-2-Hydroxyglutarate producing neo-enzymatic activity inversely correlates with frequency of the type of isocitrate dehydrogenase 1 mutations found in glioma. Acta Neuropathol. Commun., 2014, 2, 19.
[27]
Balss, J.; Pusch, S.; Beck, A.C.; Herold-Mende, C.; Kramer, A.; Thiede, C.; Buckel, W.; Langhans, C.D.; Okun, J.G.; von Deimling, A. Enzymatic assay for quantitative analysis of (D)-2-hydroxyglutarate. Acta Neuropathol., 2012, 124(6), 883-891.
43
2